Skip to main content

Sodium-glucose co-transporter-2 inhibitors

09-04-2023 | Type 2 diabetes | News

New model predicts kidney disease progression risk in type 2 diabetes

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

08-31-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

03-10-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

12-20-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

Close up of mixed medications

12-09-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

12-08-2022 | Dapagliflozin | News

Dapagliflozin may cut hospitalization risk in CKD

A post-hoc analysis of DAPA-CKD indicates that people taking dapagliflozin have a reduced risk for hospitalization, for causes not limited to cardiac or renal.

12-06-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.